Inflation

45L Energy Efficient Tax Credit (2024): Guide on Requirements and How To Claim Published by Better Business Advice

Retrieved on: 
Friday, March 8, 2024
Professional Services, Other Energy, Residential Building & Real Estate, Energy, Construction & Property, Building Systems, Accounting, Acquisition, Inflation, ETS, IECC, Partnership, International Energy Conservation Code, Heat, IRS, Certification, EPA, IRA, Act, Credit, Renewable energy

Better Business Advice has released a comprehensive guide on how to claim the 45L Energy Efficient Tax Credit, highlighting Engineered Tax Services (ETS) as the go-to tax expert for navigating this federal incentive.

Key Points: 
  • Better Business Advice has released a comprehensive guide on how to claim the 45L Energy Efficient Tax Credit, highlighting Engineered Tax Services (ETS) as the go-to tax expert for navigating this federal incentive.
  • The 45L Energy Efficient Tax Credit, a federal incentive, encourages the building of energy-efficient residences by offering credits from $500 to $5,000 per unit, based on the property's certification.
  • A significant enhancement comes with the merger of the 45L Tax Credit with Low-Income Housing Tax Credits (LIHTCs), bolstering the effectiveness of the credit.
  • Better Business Advice's guide to claiming the 45L Energy Efficient Tax Credit, with Engineered Tax Services recommended as the tax expert, is set to empower stakeholders in the residential construction industry to embrace sustainable practices while leveraging federal incentives for energy efficiency.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Retrieved on: 
Thursday, March 7, 2024
Infectious Diseases, General Health, Health, Other Health, Inflation, Senior, Immunization, GSK, Education, Physician, Hope, Entrepreneurship, Vaccine, Vaccination, American Lung Association, Patient, Request, IRA, Health equity, Infection, Medicaid, GSK plc, Pharmaceutical industry

GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.
  • The COiMMUNITY Initiative complements recent industry and regulatory efforts to expand and improve adult vaccine availability, coverage and access.
  • GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination.
  • GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.

Monoamine Oxidase Type-B (MAO-B) Inhibitors for 7 MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Pharmaceutical, Therapy, Key, Inflation, Competitive landscape, Monoamine oxidase, Physician, News, Opinion, SWOT, EU4, Inhibitor, Safety, HTA, Patient, Disease, Drug, Mutation, Pharmaceutical industry

The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors.

Grants Works Consulting Hosts Federal Grant Funding and Management Summit

Retrieved on: 
Wednesday, March 6, 2024
White House, Federal Government, Other Professional Services, Climate Change, Other Education, Consulting, Small Business, Training, Education, Accounting, Professional Services, Environmental Policy, Environment, Public Policy, Government, Science, DEI (Diversity, Equity and Inclusion), Research, Enterprise software, Inflation, The American Prospect, Climate, ATL, Oversight, Management, Commerce, Economic justice, Government Executive, Emory University, Equity, Organization, Consultant, Publication, Pharmaceutical industry

Grants Works Consulting will host its Federal Grant Funding and Management Summit at Commerce Club ATL in Atlanta, Georgia on Thursday, March 28, 2024.

Key Points: 
  • Grants Works Consulting will host its Federal Grant Funding and Management Summit at Commerce Club ATL in Atlanta, Georgia on Thursday, March 28, 2024.
  • Grants Works wants to be part of the solution and we’re doing it by hosting the summit,” said Grants Works’ CEO, Patrice Davis.
  • To address this information gap, the team at Grants Works selected speakers and crafted sessions so attendees leave the summit informed about what it takes to obtain and manage federal grant funding.
  • Grants Works Consulting is a federal grant consulting firm based in Atlanta, GA. We provide a range of pre- and post-award services to support clients as they identify, obtain, manage, and comply with federal and other government grants.

Baker Tilly Launches End-to-End Compliance Solution for Prevailing Wage & Apprenticeship Requirements in the Inflation Reduction Act

Retrieved on: 
Monday, March 4, 2024
Professional Services, Commercial Building & Real Estate, Finance, Construction & Property, Urban Planning, Consulting, Accounting, Inflation, CPA, Education, File, Davis–Bacon Act of 1931, Documentation, History, Organization, LLP, IRA, Construction

Leading advisory CPA firm Baker Tilly US, LLP (Baker Tilly) today announced the launch of an end-to-end compliance solution to help clean energy projects earn enhanced credits under the Inflation Reduction Act (IRA) by meeting Prevailing Wage & Apprenticeship (PW&A) requirements.

Key Points: 
  • Leading advisory CPA firm Baker Tilly US, LLP (Baker Tilly) today announced the launch of an end-to-end compliance solution to help clean energy projects earn enhanced credits under the Inflation Reduction Act (IRA) by meeting Prevailing Wage & Apprenticeship (PW&A) requirements.
  • The new solution provides organizations implementing clean energy projects with the technology, processes, and resources to establish, monitor and document all three pillars of compliance: prevailing wage, apprenticeship and penalties.
  • Monthly reports on prevailing wage and apprenticeship compliance are generated for each project and retained for reporting and filing purposes.
  • Learn more about Baker Tilly’s prevailing wage and apprenticeship compliance management solution: bakertilly.com/specialties/prevailing-wage-and-apprenticeship-bonus-credit-solutions .

179D Tax Deduction (2024): Guide on How To Claim Published by Better Business Advice

Retrieved on: 
Friday, March 1, 2024
Professional Services, Business, Environment, Commercial Building & Real Estate, Green Technology, Construction & Property, Accounting, Documentation, HVAC, Inflation, Real estate investment trust, Tax, IRS, Certification, Energy Policy Act, ETS, Life insurance

Better Business Advice takes readers through a step-by-step process on how to claim the deduction, emphasizing the importance of each phase from assessing project eligibility to engaging qualified professionals for certification.

Key Points: 
  • Better Business Advice takes readers through a step-by-step process on how to claim the deduction, emphasizing the importance of each phase from assessing project eligibility to engaging qualified professionals for certification.
  • The guide underscores the significance of maintaining detailed documentation as a critical component for substantiating the deduction during IRS audits.
  • Addressing the challenges and considerations inherent in claiming the 179D deduction, Better Business Advice underscores the indispensable role of Engineered Tax Services .
  • For more information on the 179D Tax Deductions and to access the complete guide, visit Better Business Advice's website .

HealthTrust Executives Featured at FAH Conference and Business Expo

Retrieved on: 
Thursday, February 29, 2024
Nursing, Medical Supplies, Hospitals, Consulting, Professional Services, Practice Management, Health, Pharmaceutical, General Health, Strategic sourcing, Inflation, Hospital, FAH, Multimedia, MBA, Doctor of Pharmacy, Federation of American Hospitals, Conference, COVID-19, Research, Management

View the full release here: https://www.businesswire.com/news/home/20240229467495/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240229467495/en/
    HealthTrust executives and subject matter experts will provide thought leadership, supply chain expertise and industry perspectives during insightful sessions and discussions over the three-day event.
  • The team will review global supply chain dynamics, hospital trends since COVID-19, the GPO’s expectations of suppliers, and the value of being a HealthTrust contracted supplier.
  • The panel will also share innovative ways to address inflationary pressures and Value Based Care in a clinically integrated supply chain.
  • The FAH Conference and Business Exposition is an annual forum for healthcare suppliers to connect with decision makers from group purchasing organizations, hospital systems and integrated delivery networks.

Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Key, Inflation, Competitive landscape, Physician, News, Opinion, SWOT, EU4, AIS, Safety, HTA, Patient, Clinical trial, Disease, Enzyme inhibitor, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Aromatase Inhibitors (AIs) market report provides insights around existing treatment practices in patients with Aromatase Inhibitors (AIs), approved (if any) and emerging Aromatase Inhibitors (AIs), market share of individual therapies, patient pool eligible for treatment with Aromatase Inhibitors (AIs), along with current and forecasted 7MM Aromatase Inhibitors (AIs) market size from 2020-2034 by therapies and by indication.
  • Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.
  • This section will include details on changing Aromatase Inhibitors (AIs) market dynamics post initiation of clinical development activities of the inhibitor.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Pharmaceutical, Health, Therapy, Inflation, Competitive landscape, PCSK9, Proprotein convertase, Physician, News, SWOT, EU4, Safety, HTA, Patient, Disease, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market report provides insights around existing treatment practices in patients with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, approved (if any) and emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, along with current and forecasted 7MM Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market size from 2020-2034 by therapies and by indication.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors marketed drug section will provide detailed drug profiles of already approved therapies.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.

Constellation Forecasts Strong Earnings Growth in 2024 and Beyond as Demand and Support for Clean Energy Builds

Retrieved on: 
Tuesday, February 27, 2024
Other Energy, Utilities, Environment, Sustainability, Alternative Energy, Green Technology, Energy, Constellation, Analysis, Inflation, ITEM, Risk, Annual report, Financial statement, Investment, Digital, Growth, Public opinion, PTC, Hydrogen, Carbon, Earnings, Commitment, Part Two, Commercial, GAAP, C&I, Nuclear energy, Webcast, Policy, Electricity, Result, Security (finance), IRA, EPS, Wind, Renewable energy

“State and federal policies, bipartisan political support, public opinion surveys and increased customer demand for reliable and clean energy all point to strong and growing support for nuclear energy to power our economy for decades to come.

Key Points: 
  • “State and federal policies, bipartisan political support, public opinion surveys and increased customer demand for reliable and clean energy all point to strong and growing support for nuclear energy to power our economy for decades to come.
  • The PTC provides revenue visibility and also preserves Constellation’s ability to capture upside from tightening power market conditions.
  • The nation’s top technology firms have set goals to power this growth with clean and dependable energy.
  • Growing recognition of nuclear energy as a reliable clean energy resource creates opportunities for Constellation to forge new customer relationships and capture additional value from our 180 million MWh of annual clean energy output.